Although immunotherapies such as programmed cell death Protein 1 (PD‐1) inhibitors have been used post‐transplant, they carry a significant risk of severe graft‐versus‐host disease (GVHD) [5, 6]. The gene discussed is PDCD1; the disease is graft versus host disease.